Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1989 Jan;65(759):1–6. doi: 10.1136/pgmj.65.759.1

Therapeutic uses of beta-adrenoceptor blocking drugs in the central nervous system in man.

P Turner 1
PMCID: PMC2429145  PMID: 2571143

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler L. A., Reiter S., Angrist B., Rotrosen J. Pindolol and propranolol in neuroleptic-induced akathisia. Am J Psychiatry. 1987 Sep;144(9):1241–1242. doi: 10.1176/ajp.144.9.1241a. [DOI] [PubMed] [Google Scholar]
  2. Adler L., Angrist B., Peselow E., Corwin J., Maslansky R., Rotrosen J. A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry. 1986 Jul;149:42–45. doi: 10.1192/bjp.149.1.42. [DOI] [PubMed] [Google Scholar]
  3. Adler L., Angrist B., Peselow E., Corwin J., Rotrosen J. Efficacy of propranolol in neuroleptic-induced akathesia. J Clin Psychopharmacol. 1985 Jun;5(3):164–166. [PubMed] [Google Scholar]
  4. Bardwell A., Trott J. A. Stroke in migraine as a consequence of propranolol. Headache. 1987 Jul;27(7):381–383. doi: 10.1111/j.1526-4610.1987.hed2707381.x. [DOI] [PubMed] [Google Scholar]
  5. Brismar K., Mogensen L., Wetterberg L. Depressed melatonin secretion in patients with nightmares due to beta-adrenoceptor blocking drugs. Acta Med Scand. 1987;221(2):155–158. doi: 10.1111/j.0954-6820.1987.tb01260.x. [DOI] [PubMed] [Google Scholar]
  6. Cunnane J. G., Blackwood G. W. Psychosis with propranolol: still not recognized? Postgrad Med J. 1987 Jan;63(735):57–58. doi: 10.1136/pgmj.63.735.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Diamond S., Solomon G. D., Freitag F. G., Mehta N. D. Long-acting propranolol in the prophylaxis of migraine. Headache. 1987 Feb;27(2):70–72. doi: 10.1111/j.1526-4610.1987.hed2702070.x. [DOI] [PubMed] [Google Scholar]
  8. Dupuis B., Catteau J., Dumon J. P., Libert C., Petit H. Comparison of propranolol, sotalol, and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry. 1987 Jun;144(6):802–805. doi: 10.1176/ajp.144.6.802. [DOI] [PubMed] [Google Scholar]
  9. Fagerström K. O., Hugdahl K., Lundström N. Effect of beta-receptor blockade on anxiety with reference to the three-systems model of phobic behavior. Neuropsychobiology. 1985;13(4):187–193. doi: 10.1159/000118186. [DOI] [PubMed] [Google Scholar]
  10. Findley L. J., Koller W. C. Essential tremor: a review. Neurology. 1987 Jul;37(7):1194–1197. doi: 10.1212/wnl.37.7.1194. [DOI] [PubMed] [Google Scholar]
  11. Frohlich E. D. Beta-blockers and mental performance. Arch Intern Med. 1988 Apr;148(4):777–778. [PubMed] [Google Scholar]
  12. Gengo F. M., Fagan S. C., de Padova A., Miller J. K., Kinkel P. R. The effect of beta-blockers on mental performance on older hypertensive patients. Arch Intern Med. 1988 Apr;148(4):779–784. [PubMed] [Google Scholar]
  13. Gorman J. M., Liebowitz M. R., Fyer A. J., Campeas R., Klein D. F. Treatment of social phobia with atenolol. J Clin Psychopharmacol. 1985 Oct;5(5):298–301. doi: 10.1097/00004714-198510000-00009. [DOI] [PubMed] [Google Scholar]
  14. Gorman W. P., Cooper R., Pocock P., Campbell M. J. A comparison of primidone, propranolol, and placebo in essential tremor, using quantitative analysis. J Neurol Neurosurg Psychiatry. 1986 Jan;49(1):64–68. doi: 10.1136/jnnp.49.1.64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Granville-Grossman K. L., Turner P. The effect of propranolol on anxiety. Lancet. 1966 Apr 9;1(7441):788–790. doi: 10.1016/s0140-6736(66)91863-0. [DOI] [PubMed] [Google Scholar]
  16. Greendyke R. M., Kanter D. R. Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations. J Clin Psychopharmacol. 1987 Jun;7(3):178–182. [PubMed] [Google Scholar]
  17. Greendyke R. M., Kanter D. R. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study. J Clin Psychiatry. 1986 Aug;47(8):423–426. [PubMed] [Google Scholar]
  18. Greendyke R. M., Schuster D. B., Wooton J. A. Propranolol in the treatment of assaultive patients with organic brain disease. J Clin Psychopharmacol. 1984 Oct;4(5):282–285. [PubMed] [Google Scholar]
  19. Hallström C., Crouch G., Robson M., Shine P. The treatment of tranquilizer dependence by propranolol. Postgrad Med J. 1988;64 (Suppl 2):40–44. [PubMed] [Google Scholar]
  20. Hiner B. C., Roth H. L., Peroutka S. J. Antimigraine drug interactions with 5-hydroxytryptamine1A receptors. Ann Neurol. 1986 May;19(5):511–513. doi: 10.1002/ana.410190518. [DOI] [PubMed] [Google Scholar]
  21. Hod H., Har-Zahav J., Kaplinsky N., Frankl O. Pindolol-induced tremor. Postgrad Med J. 1980 May;56(655):346–347. doi: 10.1136/pgmj.56.655.346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Jefferson D., Wharrad H. J., Birmingham A. T., Patrick J. M. The comparative effects of ICI 118551 and propranolol on essential tremor. Br J Clin Pharmacol. 1987 Dec;24(6):729–734. doi: 10.1111/j.1365-2125.1987.tb03238.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Johnson R. H., Hornabrook R. W., Lambie D. G. Comparison of mefenamic acid and propranolol with placebo in migraine prophylaxis. Acta Neurol Scand. 1986 May;73(5):490–492. doi: 10.1111/j.1600-0404.1986.tb04591.x. [DOI] [PubMed] [Google Scholar]
  24. King D. J., Devaney N. M., Gilbert J. K. A double-blind placebo controlled trial of a selective beta 2 adrenoceptor antagonist (ICI 118551) in chronic anxiety. Int Clin Psychopharmacol. 1987 Jul;2(3):191–200. doi: 10.1097/00004850-198707000-00002. [DOI] [PubMed] [Google Scholar]
  25. Kraus M. L., Gottlieb L. D., Horwitz R. I., Anscher M. Randomized clinical trial of atenolol in patients with alcohol withdrawal. N Engl J Med. 1985 Oct 10;313(15):905–909. doi: 10.1056/NEJM198510103131501. [DOI] [PubMed] [Google Scholar]
  26. Madden D. J., Blumenthal J. A., Ekelund L. G., Krantz D. S., Light K. C., McKee D. C. Memory performance by mild hypertensives following beta-adrenergic blockade. Psychopharmacology (Berl) 1986;89(1):20–24. doi: 10.1007/BF00175183. [DOI] [PubMed] [Google Scholar]
  27. Manchanda R., Hirsch S. R. Does propranolol have an antipsychotic effect? A placebo-controlled study in acute schizophrenia. Br J Psychiatry. 1986 Jun;148:701–707. doi: 10.1192/bjp.148.6.701. [DOI] [PubMed] [Google Scholar]
  28. Mattes J. A. Metoprolol for intermittent explosive disorder. Am J Psychiatry. 1985 Sep;142(9):1108–1109. doi: 10.1176/ajp.142.9.1108. [DOI] [PubMed] [Google Scholar]
  29. Mattes J. A. Propranolol for adults with temper outbursts and residual attention deficit disorder. J Clin Psychopharmacol. 1986 Oct;6(5):299–302. [PubMed] [Google Scholar]
  30. Maura G., Ulivi M., Raiteri M. (-)-Propranolol and (+/-)-cyanopindolol are mixed agonists-antagonists at serotonin autoreceptors in the hippocampus of the rat brain. Neuropharmacology. 1987 Jul;26(7A):713–717. doi: 10.1016/0028-3908(87)90232-2. [DOI] [PubMed] [Google Scholar]
  31. Mikkelsen B., Pedersen K. K., Christiansen L. V. Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo. Acta Neurol Scand. 1986 Apr;73(4):423–427. doi: 10.1111/j.1600-0404.1986.tb03299.x. [DOI] [PubMed] [Google Scholar]
  32. Olerud B., Gustavsson C. L., Furberg B. Nadolol and propranolol in migraine management. Headache. 1986 Nov;26(10):490–493. doi: 10.1111/j.1526-4610.1986.hed2610490.x. [DOI] [PubMed] [Google Scholar]
  33. Patel L., Turner P. Central actions of beta-adrenoceptor blocking drugs in man. Med Res Rev. 1981 Winter;1(4):387–410. doi: 10.1002/med.2610010405. [DOI] [PubMed] [Google Scholar]
  34. Peet M., Ali S. Propranolol and atenolol in the treatment of anxiety. Int Clin Psychopharmacol. 1986 Oct;1(4):314–319. doi: 10.1097/00004850-198610000-00005. [DOI] [PubMed] [Google Scholar]
  35. Peet M. The treatment of anxiety with beta-blocking drugs. Postgrad Med J. 1988;64 (Suppl 2):45–49. [PubMed] [Google Scholar]
  36. Pfaffenrath V., Kellhammer U., Pöllmann W. Combination headache: practical experience with a combination of a beta-blocker and an antidepressive. Cephalalgia. 1986;6 (Suppl 5):25–32. doi: 10.1177/03331024860060S503. [DOI] [PubMed] [Google Scholar]
  37. Pradalier A., Giroud M., Dry J. Somnambulism, migraine and propranolol. Headache. 1987 Mar;27(3):143–145. doi: 10.1111/j.1526-4610.1987.hed2703143.x. [DOI] [PubMed] [Google Scholar]
  38. Ratey J. J., Mikkelsen E., Sorgi P., Zuckerman H. S., Polakoff S., Bemporad J., Bick P., Kadish W. Autism: the treatment of aggressive behaviors. J Clin Psychopharmacol. 1987 Feb;7(1):35–41. [PubMed] [Google Scholar]
  39. Seivewright N., Tyrer P. J. Use of beta-blocking drugs in withdrawal states. Postgrad Med J. 1984;60 (Suppl 2):47–50. [PubMed] [Google Scholar]
  40. Sheard M. H. Clinical pharmacology of aggressive behavior. Clin Neuropharmacol. 1984;7(3):173–183. [PubMed] [Google Scholar]
  41. Shore J. H., Fraunfelder F. T., Meyer S. M. Psychiatric side effects from topical ocular timolol, a beta-adrenergic blocker. J Clin Psychopharmacol. 1987 Aug;7(4):264–267. [PubMed] [Google Scholar]
  42. Silver J. M., Yudofsky S. C., Kogan M., Katz B. L. Elevation of thioridazine plasma levels by propranolol. Am J Psychiatry. 1986 Oct;143(10):1290–1292. doi: 10.1176/ajp.143.10.1290. [DOI] [PubMed] [Google Scholar]
  43. Sorgi P. J., Ratey J. J., Polakoff S. Beta-adrenergic blockers for the control of aggressive behaviors in patients with chronic schizophrenia. Am J Psychiatry. 1986 Jun;143(6):775–776. doi: 10.1176/ajp.143.6.775. [DOI] [PubMed] [Google Scholar]
  44. Teräväinen H., Huttunen J., Larsen T. A. Selective adrenergic beta-2-receptor blocking drug, ICI-118.551, is effective in essential tremor. Acta Neurol Scand. 1986 Jul;74(1):34–37. doi: 10.1111/j.1600-0404.1986.tb04622.x. [DOI] [PubMed] [Google Scholar]
  45. Tfelt-Hansen P. Efficacy of beta-blockers in migraine. A critical review. Cephalalgia. 1986;6 (Suppl 5):15–24. doi: 10.1177/03331024860060S502. [DOI] [PubMed] [Google Scholar]
  46. Turner P. Beta-blocking drugs in migraine. Postgrad Med J. 1984;60 (Suppl 2):51–55. [PubMed] [Google Scholar]
  47. Weerasuriya K., Patel L., Turner P. Beta-adrenoceptor blockade and migraine. Cephalalgia. 1982 Mar;2(1):33–45. doi: 10.1046/j.1468-2982.1982.0201033.x. [DOI] [PubMed] [Google Scholar]
  48. Ziegler D. K., Hurwitz A., Hassanein R. S., Kodanaz H. A., Preskorn S. H., Mason J. Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch Neurol. 1987 May;44(5):486–489. doi: 10.1001/archneur.1987.00520170016015. [DOI] [PubMed] [Google Scholar]
  49. al-Qassab H., Cleeves L. A., Francis P. L., al-Sereiti M. R., Findley L., Hedges A., Silman R., Turner P. Is there a central nervous withdrawal syndrome associated with discontinuing long-term treatment with propranolol? Hum Toxicol. 1988 May;7(3):249–254. doi: 10.1177/096032718800700303. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES